- Home
- KALV vs CURV Comparison
KALV vs CURV Comparison
Compare KALV & CURV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- CURV
- Stock Information
- Founded
- KALV N/A
- CURV 2001
- Country
- KALV United States
- CURV United States
- Employees
- KALV N/A
- CURV N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- CURV Clothing/Shoe/Accessory Stores
- Sector
- KALV Health Care
- CURV Consumer Discretionary
- Exchange
- KALV Nasdaq
- CURV Nasdaq
- Market Cap
- KALV 796.4M
- CURV 215.9M
- IPO Year
- KALV N/A
- CURV 2021
- Fundamental
- Price
- KALV $13.88
- CURV $1.87
- Analyst Decision
- KALV Strong Buy
- CURV Hold
- Analyst Count
- KALV 8
- CURV 5
- Target Price
- KALV $26.43
- CURV $3.09
- AVG Volume (30 Days)
- KALV 990.9K
- CURV 1.0M
- Earning Date
- KALV 09-11-2025
- CURV 09-04-2025
- Dividend Yield
- KALV N/A
- CURV N/A
- EPS Growth
- KALV N/A
- CURV N/A
- EPS
- KALV N/A
- CURV 0.03
- Revenue
- KALV $1,426,000.00
- CURV $1,068,099,000.00
- Revenue This Year
- KALV N/A
- CURV N/A
- Revenue Next Year
- KALV $213.43
- CURV N/A
- P/E Ratio
- KALV N/A
- CURV $62.04
- Revenue Growth
- KALV N/A
- CURV N/A
- 52 Week Low
- KALV $7.30
- CURV $1.62
- 52 Week High
- KALV $17.28
- CURV $7.19
- Technical
- Relative Strength Index (RSI)
- KALV 48.68
- CURV 38.79
- Support Level
- KALV $13.35
- CURV $1.80
- Resistance Level
- KALV $14.25
- CURV $1.92
- Average True Range (ATR)
- KALV 1.03
- CURV 0.15
- MACD
- KALV -0.15
- CURV 0.01
- Stochastic Oscillator
- KALV 16.05
- CURV 29.88
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
About CURV Torrid Holdings Inc.
Torrid Holdings Inc is a direct-to-consumer brand of apparel, intimates, and accessories in North America. The company is focused on fit and offers high-quality products across a broad assortment that includes tops, bottoms, denim, dresses, intimates, activewear, footwear, and accessories. The company has one reportable segment, which includes the operation of the e-commerce platform and stores. The company generates revenue from the sale of apparel, intimates, and accessories through its e-commerce platform and its store locations.